1. Effectiveness of switching to rituximab over fingolimod or dimethyl fumarate after natalizumab in preventing disease activity in multiple sclerosis;Alvarez;Neurology,2015
2. Biogen Inc. TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use: US prescribing Information. 2016a; http://www.tecfidera.com/pdfs/full-prescribing-info.pdf. Accessed May 5, 2016.
3. Biogen Inc. TYSABRI (natalizumab) prescribing information. 2016b; https://www.tysabri.com/content/dam/commercial/multiple-sclerosis/tysabri/pat/en_us/pdfs/tysabri_prescribing_information.pdf. Accessed October 16, 2016.
4. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results;Butzkueven;J. Neurol. Neurosurg. Psychiatry,2014
5. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE;Chen;J. Clin. Investig.,2014